🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06566729
Active, not recruiting Observational

MRD in High-risk EBC

NCT06566729 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Observational
Started
2023-06-01
Last updated
2024-08-22

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

Peripheral blood sample collection

Peripheral blood sample collection: In this study, peripheral blood samples would be collected before adjuvant chemotherapy, after adjuvant chemotherapy and every 3 months thereafter until 2 years after surgery.

Study summary

This study is a multicenter, prospective, observational cohort study, 125 patients with early-stage high-risk breast cancer will be enrolled, perioperative surgical specimens, peripheral blood specimens before and after adjuvant therapy and follow-up will be collected, and the predictive effect of MRD of molecular residual lesions on recurrence events and drug efficacy will be evaluated through dynamic monitoring, so as to further accurately stratify the risk and guide clinical intervention.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Informed consent signed * Age ≥18 years old * Undergoing breast surgery, the surgical specimen was diagnosed as invasive breast cancer by the central laboratory and met any of the following conditions: 1. Hormone receptor-positive/HER2-negative breast cancer, the number of lymph node metastases ≥ 4; 2. HER2-positive breast cancer, lymph node metastasis≥4; 3. Triple negative breast cancer, the number of lymph node metastases ≥ 1; * ECOG 0-1 * Willing to cooperate in clinical research-related treatment and follow-up, with good patient compliance Exclusion Criteria: * Confirmed distant metastases site * History of other malignancy * Psychopaths or other reasons unable to comply with treatment * Concomitant uncontrolled lung disease, severe liver and kidney disease, severe infection, active peptic ulcer requiring treatment, coagulation disorders, connective tissue disease, or bone marrow suppression, and cannot tolerate chemotherapy and other related treatments * HIV carrier or HBC/HCV infected * Current or recent (within 30 days prior to enrollment) use of participation in another investigational program or use of another investigational drug

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital Shanghai Shanghai Municipality

More Shanghai Jiao Tong University School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06566729 on ClinicalTrials.gov ↗ ← All trials in China